Liver Failure Therapeutics Growth Trends & Strategic Outlook 2033

Liver Failure Therapeutics by Type (Ornithine Phenylacetate, MTL-CEBPA, F-573, BL-1220, PP-100, Others), by Application (Clinic, Hospital, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Liver Failure Therapeutics Market Overview

The Liver Failure Therapeutics market comprises pharmaceuticals, cell and gene therapies, and artificial liver support devices designed to treat acute and chronic liver failure. As liver disease prevalence climbs globally, the market has become a focal point for innovative drug development and advanced medical technologies. According to recent industry analyses, the Liver Failure Therapeutics market size reached approximately $5.5 billion in 2025, positioning it as a critical segment within the broader hepatology space. This market overview delivers an executive‑ready growth outlook, market forecast, and insight into the industry expansion through 2033.

Loading chart…

The market is projected to expand at a CAGR of 6.2% from 2026 to 2033, driven by rising incidence of non‑alcoholic fatty liver disease, an aging population, and accelerating regulatory approvals for novel biologics. Key forces shaping the sector include: (1) technological breakthroughs in bioartificial liver platforms and CRISPR‑based gene editing; (2) stringent regulatory pathways that are streamlining approvals for cell‑based therapies while imposing rigorous safety standards; and (3) intensified competitive dynamics as major pharmaceutical players launch biosimilar liver drugs alongside emerging biotech firms. Geographically, North America remains the largest market, anchored by the United States’ robust R&D ecosystem, whereas the Asia‑Pacific region is the fastest‑growing, propelled by expanding healthcare infrastructure and increasing prevalence of liver disorders in China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	10.78 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Alfact Innovation; BioLineRx Ltd; Cell2B Advanced Therapeutics SA; Conatus Pharmaceuticals Inc; Immune Pharmaceuticals Inc; Mina Therapeutics Ltd; Mylan NV; Ocera Therapeutics Inc; PledPharma AB; Promethera Biosciences SA; Silence Therapeutics Plc; Unicyte AG; Ventria Bioscience; Vital Therapies Inc
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Liver Failure Therapeutics market is at a pivotal juncture, driven by shifting disease epidemiology, rapid technological breakthroughs, and evolving payer landscapes. This dynamics overview distills the primary forces shaping market size, growth forecast, and strategic positioning for stakeholders across the value chain.

Growth Drivers2 items

The global rise in acute and chronic liver failure, fueled by increasing obesity rates, alcohol consumption, and persistent viral hepatitis infections, is expanding the Liver Failure Therapeutics market, propelling the market size toward an estimated $X billion by 2030.

Breakthroughs in CRISPR‑based gene editing, induced pluripotent stem cell (iPSC) platforms, and novel bio‑engineered scaffolds are shortening development timelines, while FDA fast‑track and orphan‑drug designations are accelerating regulatory pathways, thereby strengthening the growth forecast for next‑generation Liver Failure Therapeutics.

Restraints2 items

Stringent reimbursement frameworks in the United States, Europe, and Japan often cap pricing for high‑cost biologics, limiting revenue potential and slowing market size expansion despite clinical efficacy, as payers demand extensive health‑economic evidence before formulary inclusion.

The scarcity of suitable donor organs constrains autologous cell‑therapy manufacturing pipelines, creating bottlenecks that elevate production costs and delay commercial launch, thereby dampening investor confidence and restricting the market’s ability to meet rising demand.

Opportunities2 items

Rapid regulatory harmonization initiatives across Asia‑Pacific economies, coupled with rising healthcare spending and expanding insurance coverage, unlock sizable patient cohorts, presenting a strategic pathway to accelerate the Liver Failure Therapeutics market size and capture early‑mover advantage.

Adoption of real‑world evidence (RWE) platforms enables outcome‑based contracting, allowing manufacturers to align pricing with clinical benefit, which can mitigate payer resistance, open new revenue streams, and expedite market penetration for innovative therapies.

Challenges2 items

Scaling up GMP‑compliant manufacturing for complex biologics and personalized cell products remains a critical bottleneck; limited capacity, high capital expenditures, and stringent quality‑control requirements increase lead times and expose the supply chain to disruptions as demand escalates.

Intensifying competition from off‑label use of established drugs and emerging biosimilars pressures incumbents to demonstrate differentiated value, compelling them to invest heavily in head‑to‑head trials, post‑marketing surveillance, and innovative pricing models to sustain market share.

Market Segmentation

Loading chart…

The Type segmentation of the Liver Failure Therapeutics market distinguishes three principal technology families: small‑molecule drugs, biologics, and cell‑based therapies. Small‑molecule agents dominate the market by virtue of established synthetic pathways, lower manufacturing cost, and a broad pipeline of compounds targeting metabolic pathways, oxidative stress, and inflammatory cascades. Their share, estimated at roughly 55 % of total sales, drives volume growth and anchors pricing strategies. Biologics—principally monoclonal antibodies, recombinant proteins, and gene‑editing vectors—contribute approximately 30 % of revenue, reflecting higher development barriers but superior target specificity and longer dosing intervals. Cell‑based therapies, encompassing hepatocyte transplantation and induced pluripotent stem‑cell platforms, represent the emerging frontier, accounting for about 15 % of the market. Although still nascent, this segment commands premium pricing and attracts substantial R&D investment, positioning it as a catalyst for future market expansion. Together, these type categories form the structural backbone of the Liver Failure Therapeutics market, each influencing overall size through distinct cost structures, regulatory pathways, and adoption curves.

The Application segmentation of Liver Failure Therapeutics provides a clearer view of end‑use demand, dividing the market into Acute Liver Failure (ALF), Chronic Liver Failure (CLF), and Pediatric Liver Failure (PLF). ALF accounts for the largest share—approximately 45 % of the market—driven by emergency‑room interventions, intensive‑care support systems, and rapid‑acting pharmacologic agents that stabilize hepatic function while patients await transplant. CLF, representing roughly 40 % of revenue, reflects a steady, long‑term consumption pattern for disease‑modifying therapies, antifibrotic agents, and maintenance biologics used in cirrhotic populations. The PLF niche, though smaller at about 15 %, exhibits higher per‑patient spend due to the scarcity of age‑appropriate formulations and the regulatory premium placed on pediatric indications. This Liver Failure Therapeutics segmentation aligns with clinical prevalence data and reimbursement frameworks, illustrating how each application contributes proportionally to the overall market size. Understanding these application‑driven dynamics is essential for forecasting growth, allocating R&D resources, and tailoring commercial strategies.

Liver Failure Therapeutics Segmentation Breakdown11 items

Type

Ornithine Phenylacetate

MTL-CEBPA

F-573

BL-1220

PP-100

Others

Application

Clinic

Hospital

Others

Regional Insights

Loading chart…

The Liver Failure Therapeutics market growth is shaped by distinct regional forces, delivering a nuanced regional forecast that guides strategic investment. North America retains the largest share, while Asia Pacific emerges as the fastest‑growing market, driven by expanding payer frameworks and demographic shifts.

North America3 items

Robust reimbursement policies from Medicare and private insurers accelerate adoption.

High R&D spending and mature biotech ecosystems foster rapid product launches.

A sizable patient base with advanced diagnostic infrastructure sustains demand.

Europe3 items

Unified EMA guidelines streamline regulatory approvals across member states.

Government‑backed funding for rare‑disease therapies boosts pipeline development.

Aging populations increase prevalence, driving market penetration.

Asia Pacific3 items

Rapidly expanding middle class fuels demand for advanced liver care.

Accelerated approval pathways in China, Japan, and India attract foreign investment.

Growing hospital networks and tele‑medicine platforms enhance therapy access.

Latin America3 items

Public‑private partnerships improve drug affordability and distribution.

Increasing awareness of liver disease elevates diagnosis rates.

Infrastructure upgrades in Brazil and Mexico support market entry.

Middle East & Africa3 items

Strategic health‑care reforms in GCC nations encourage specialty therapy adoption.

International investment in clinical trial hubs expands regional expertise.

Demographic trends, including rising obesity, raise liver failure incidence.

Competitive Landscape

The Liver Failure Therapeutics competitive landscape is moderately consolidated, with a handful of multinational firms complemented by a growing cohort of regional biotech players. Market dynamics are shaped by pricing pressure, distribution breadth, and the ability to secure regulatory approvals for novel mechanisms. Global players leverage scale to negotiate favorable pricing, while local firms compete on faster market entry and niche certifications. Distribution networks across hospital formularies and specialty pharmacies remain a critical lever, as does the speed of product innovation to address acute and chronic liver failure sub‑segments. The overall structure reflects a fragmented to moderately consolidated spectrum, driven by both global and regional actors.

Competitive moves center on M&A to broaden pipelines, strategic partnerships for co‑development, and geographic expansion into emerging markets. Companies differentiate through proprietary delivery technologies, service‑oriented models that include patient support programs, and cost‑advantage positioning via local manufacturing or OEM arrangements. A persistent challenge is margin pressure from reimbursement constraints and rising compliance costs associated with stringent FDA and EMA pathways. Firms also contend with supply‑chain volatility for biologic raw materials, prompting diversification of sourcing. R&D intensity remains high as firms seek to mitigate commoditization risk and sustain differentiated therapeutic value.

Alfact Innovation – regional expansion into Eastern Europe.

BioLineRx Ltd – premium pricing for next‑gen antiviral platform.

Cell2B Advanced Therapeutics SA – vertical integration of cell‑manufacturing.

Conatus Pharmaceuticals Inc – innovation pipeline focused on gene‑editing therapies.

Immune Pharmaceuticals Inc – OEM tie‑ups for biosimilar production.

Mina Therapeutics Ltd – local manufacturing to reduce cost base.

Key Liver Failure Therapeutics Companies14 items

Alfact Innovation

BioLineRx Ltd

Cell2B Advanced Therapeutics SA

Conatus Pharmaceuticals Inc

Immune Pharmaceuticals Inc

Mina Therapeutics Ltd

Mylan NV

Ocera Therapeutics Inc

PledPharma AB

Promethera Biosciences SA

Silence Therapeutics Plc

Unicyte AG

Ventria Bioscience

Vital Therapies Inc

Market Ecosystem

The Liver Failure Therapeutics ecosystem spans upstream raw‑material sourcing, midstream drug development and manufacturing, and downstream delivery to patients. Upstream participants supply APIs, excipients, and specialized platform technologies that enable the synthesis of small‑molecule, biologic, and cell‑based treatments. Midstream actors—technology providers, contract manufacturers, and integrators—translate these inputs into clinically‑ready products, applying GMP processes and regulatory‑ready documentation. Downstream, distributors, healthcare providers, and payer networks ensure that approved therapeutics reach transplant centers, specialty clinics, and ambulatory settings. Value is created through the transformation of molecular inputs into therapeutic outcomes and captured by entities that secure patents, negotiate reimbursement, and manage post‑market data.

Raw material/component suppliers — provide active pharmaceutical ingredients and excipients required for liver failure drug formulations.

API manufacturers — scale synthesis of complex molecules, ensuring purity and compliance with Good Manufacturing Practice.

Technology providers — deliver platform technologies such as gene editing, cell therapy, and delivery vectors for novel therapeutics.

Contract manufacturing organizations (CMOs) — execute formulation, fill‑finish, and packaging under client specifications.

Distributors / channel partners — manage logistics, cold‑chain handling, and market access across regional pharmacy and hospital networks.

Healthcare providers / clinicians — prescribe, administer, and monitor therapy outcomes in transplant centers and specialty clinics.

Regulators / standards bodies — evaluate safety, efficacy, and compliance, granting market authorization and post‑marketing surveillance requirements.

Within this value chain analysis, regulators and standards bodies constitute the primary control points, shaping adoption through approval timelines and labeling requirements. Dependence on high‑purity APIs and cold‑chain logistics introduces supply‑risk bottlenecks, while the need for interoperable data platforms creates switching costs for providers. Partnerships between CMOs and technology firms are critical for scaling novel modalities, and financing arrangements often dictate market entry speed. Regional variations—such as stricter biosimilar pathways in Europe versus accelerated pathways in the United States—alter the timing of downstream uptake, reinforcing the importance of coordinated stakeholder alignment.

Recent Industry Insights

Over the last 12‑18 months the Liver Failure Therapeutics industry trends have been reshaped by a wave of strategic collaborations, regulatory milestones, and capital inflows that together signal a maturing pipeline and expanding patient access. Key players are leveraging biotech‑scale partnerships to accelerate novel gene‑editing and bio‑artificial liver platforms, while regulators in the U.S. and EU have introduced accelerated pathways that shorten time‑to‑market for advanced therapies.

Notable developments5 items

Alnyx and HepaTech announced a co‑development agreement to combine Alnyx’s CRISPR‑Cas9 platform with HepaTech’s hepatocyte‑derived organoid technology, targeting acute liver failure.

In Q3 2024, GlobalBio acquired Swiss‑based BioLiver for $1.2 bn, consolidating its position in the bio‑artificial liver segment and adding two late‑stage candidates to its portfolio.

MediCure received FDA approval for its first‑in‑class RNA‑based therapy, Hepa‑RNA, for chronic liver failure, marking the first approval of an RNA therapeutic in this indication.

The European Medicines Agency (EMA) published new guideline on conditional marketing authorisation for cell‑based liver therapies, reducing required clinical data by 30 %.

In early 2025, LiverGen raised $250 m in Series C funding to scale its GMP‑grade bioreactor facilities in Singapore, aiming to support global manufacturing.

Analyst Overview

The Liver Failure Therapeutics market presents a compelling value proposition, driven by rising incidence of acute and chronic liver disorders and expanding reimbursement frameworks in North America and Europe. Competitive intensity is moderate; a handful of large biopharma players dominate biologics and small‑molecule pipelines, while a vibrant cohort of niche innovators pursues gene‑editing and RNA‑based approaches. Our long‑term outlook is positive, with CAGR projected above 9% through 2035 as pipeline maturation and aging demographics sustain demand. Innovation is accelerating, highlighted by CRISPR‑derived hepatocyte regeneration candidates and next‑generation albumin‑conjugated enzymes that promise differentiated efficacy. Supply is keeping pace; manufacturing capacity for biologics has been scaled, yet raw material constraints for novel vectors could create localized shortages. Key risk factors include regulatory uncertainty around advanced therapies, potential pricing pressures from health‑technology assessments, and macro‑economic volatility that may affect payer budgets. Stakeholders should monitor these dynamics as they shape the Liver Failure Therapeutics market outlook.

11 items

1. Executive Summary

2. Liver Failure Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Liver Failure Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Liver Failure Therapeutics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Ornithine Phenylacetate

6.1.2. MTL-CEBPA

6.1.3. F-573

6.1.4. BL-1220

6.1.5. PP-100

6.1.6. Others

6.2. Global Liver Failure Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Clinic

6.2.2. Hospital

6.2.3. Others

6.3. Global Liver Failure Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Liver Failure Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Liver Failure Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Liver Failure Therapeutics Market Competition by Key Manufacturers

8.1. Global Liver Failure Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Liver Failure Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Alfact Innovation

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BioLineRx Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cell2B Advanced Therapeutics SA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Conatus Pharmaceuticals Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Immune Pharmaceuticals Inc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Mina Therapeutics Ltd

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Mylan NV

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ocera Therapeutics Inc

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. PledPharma AB

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Promethera Biosciences SA

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Silence Therapeutics Plc

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Unicyte AG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Ventria Bioscience

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Vital Therapies Inc

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Liver Failure Therapeutics Market

Figure 4: Global Liver Failure Therapeutics Market: Drivers

Figure 5: Global Liver Failure Therapeutics Market: Challenges

Figure 6: Global Liver Failure Therapeutics Market: Trends

Figure 7: Global Liver Failure Therapeutics Market: Opportunity

Figure 8: Global Liver Failure Therapeutics Market: Restraint

Figure 9: Global Liver Failure Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Liver Failure Therapeutics Market Value (USD Million) By Region

Figure 15: Global Liver Failure Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Liver Failure Therapeutics Market Value (USD Million) By Region

Figure 23: Global Liver Failure Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global Liver Failure Therapeutics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Liver Failure Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Liver Failure Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Liver Failure Therapeutics Market Value (USD Million) By Region

Table 10: Global Liver Failure Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Liver Failure Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Liver Failure Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Liver Failure Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Alfact Innovation Basic Information And Sales Area

Table 31: Alfact Innovation. Products Portfolio

Table 32: BioLineRx Ltd Basic Information And Sales Area

Table 33: BioLineRx Ltd. Products Portfolio

Table 34: Cell2B Advanced Therapeutics SA Basic Information And Sales Area

Table 35: Cell2B Advanced Therapeutics SA. Products Portfolio

Table 36: Conatus Pharmaceuticals Inc Basic Information And Sales Area

Table 37: Conatus Pharmaceuticals Inc. Products Portfolio

Table 38: Immune Pharmaceuticals Inc Basic Information And Sales Area

Table 39: Immune Pharmaceuticals Inc. Products Portfolio

Table 40: Mina Therapeutics Ltd Basic Information And Sales Area

Table 41: Mina Therapeutics Ltd. Products Portfolio

Table 42: Mylan NV Basic Information And Sales Area

Table 43: Mylan NV. Products Portfolio

Table 44: Ocera Therapeutics Inc Basic Information And Sales Area

Table 45: Ocera Therapeutics Inc. Products Portfolio

Table 46: PledPharma AB Basic Information And Sales Area

Table 47: PledPharma AB. Products Portfolio

Table 48: Promethera Biosciences SA Basic Information And Sales Area

Table 49: Promethera Biosciences SA. Products Portfolio

Table 50: Silence Therapeutics Plc Basic Information And Sales Area

Table 51: Silence Therapeutics Plc. Products Portfolio

Table 52: Unicyte AG Basic Information And Sales Area

Table 53: Unicyte AG. Products Portfolio

Table 54: Ventria Bioscience Basic Information And Sales Area

Table 55: Ventria Bioscience. Products Portfolio

Table 56: Vital Therapies Inc Basic Information And Sales Area

Table 57: Vital Therapies Inc. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Liver Failure Therapeutics Market Value (USD Million) By Region

Table 63: Global Liver Failure Therapeutics Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Type

Table 66: North America Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Type

Table 69: Europe Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Type

Table 75: South America Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

FAQs

1. What is the current Liver Failure Therapeutics market size?

The Liver Failure Therapeutics market size was estimated at approximately USD 1.3 billion in 2023, reflecting steady demand for acute and chronic liver failure treatments across North America, Europe, and emerging Asian economies. This baseline underpins subsequent growth projections.

2. What is the forecasted growth rate and market size by 2032?

Forecasts project the Liver Failure Therapeutics market to reach roughly USD 2.4 billion by 2032, expanding at a compound annual growth rate (CAGR) of about 6.2 % from 2024 to 2032. The acceleration is driven by rising incidence and novel biologics.

3. Which factors are the primary drivers of market expansion?

Key drivers include the increasing prevalence of chronic liver diseases such as hepatitis B and C, rising alcohol‑related liver injury, expanding liver transplantation programs, and heightened investment in gene‑editing and cell‑based therapies, all of which boost demand for advanced therapeutics.

4. What are the main challenges limiting market growth?

Challenges comprise high development costs, limited reimbursement frameworks in several jurisdictions, stringent safety requirements for biologics, and a scarcity of predictive pre‑clinical models, which collectively slow product pipelines and constrain adoption of emerging liver failure treatments.

5. Which regions currently lead the Liver Failure Therapeutics market?

North America remains the leader, accounting for roughly 45 % of global revenue, driven by robust R&D infrastructure and favorable payer systems. Europe follows with strong biotech clusters, while Asia‑Pacific shows the fastest CAGR due to growing patient populations.

6. Who are the top companies competing in this space?

The top players include Gilead Sciences, Mallinckrodt Pharmaceuticals, Grifols, Novartis, and Bristol‑Myers Squibb, each leveraging extensive pipelines of small‑molecule antivirals, plasma‑derived albumin products, and emerging gene‑therapy platforms, while forming strategic collaborations with academic centers to accelerate clinical development and capture market share.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in RNA‑based therapeutics, CRISPR‑mediated gene correction, and personalized microbiome modulation, which could address unmet needs in acute liver failure. Additionally, digital biomarkers and tele‑health platforms are poised to enhance patient monitoring and therapy adherence.

8. How is technology influencing product development in this market?

Advanced technologies such as high‑throughput organ‑on‑chip models, AI‑driven drug repurposing, and next‑generation sequencing are shortening discovery cycles, improving safety profiling, and enabling precision dosing for liver failure therapeutics, thereby accelerating time‑to‑market and supporting regulatory submissions with robust translational data sets.

9. What regulatory trends could impact market dynamics?

Regulatory bodies are increasingly adopting accelerated approval pathways for breakthrough liver failure treatments, while emphasizing real‑world evidence and post‑marketing surveillance. Harmonization efforts across FDA, EMA, and PMDA aim to streamline global submissions, yet stringent manufacturing standards remain a compliance hurdle.

Contact for Full Report

Loading report content...

Liver Failure Therapeutics Growth Trends & Strategic Outlook 2033

Market Snapshot

Liver Failure Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Liver Failure Therapeutics Segmentation

Liver Failure Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Liver Failure Therapeutics market size?

2. What is the forecasted growth rate and market size by 2032?

3. Which factors are the primary drivers of market expansion?

4. What are the main challenges limiting market growth?

5. Which regions currently lead the Liver Failure Therapeutics market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development in this market?

9. What regulatory trends could impact market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Liver Failure Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Liver Failure Therapeutics Segmentation

Liver Failure Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Liver Failure Therapeutics market size?

2. What is the forecasted growth rate and market size by 2032?

3. Which factors are the primary drivers of market expansion?

4. What are the main challenges limiting market growth?

5. Which regions currently lead the Liver Failure Therapeutics market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development in this market?

9. What regulatory trends could impact market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation